Synthesis, characterisation and biological activity of the ruthenium(II) complexes of the N4-tetradentate (N4-TL), 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2).
Abstract |
A series of complexes of the type rac-cis-β-[Ru(N4-TL)(N2-bidentates)]2+ (where N4-TL = 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2, N4-TL-2) and N2-bidentates = 1,10- phenanthroline (phen, Ru-2), dipyrido[3,2-d:2',3'-f] quinoxaline (dpq, Ru-3), 7,8-dimethyl-dipyrido[3,2-a:2',3'-c] phenazine (dppzMe2,Ru-4), 2-phenyl-1H-imidazo[4,5-f][1,10] phenanthroline (phenpyrBz, Ru-5), 2-(p-tolyl)-1H-imidazo[4,5-f][1,10] phenanthroline (phenpyrBzMe, Ru-6), 2-(4-nitrophenyl)-1H-imidazo[4,5-f][1,10] phenanthroline (phenpyrBzNO2,Ru-7), were synthesised and characterised and X-ray crystallography of Ru-5 obtained. The in vitro cytotoxicity assays revealed that Ru-6 was 5, 2 and 19-fold more potent than oxaliplatin, cisplatin, and carboplatin, respectively displaying an average GI50 value of ≈ 0.76 μM against a panel of 11 cancer cell lines.
|
Authors | Aleksandra Bjelosevic, Jennette Sakoff, Jayne Gilbert, Yingjie Zhang, Brondwyn McGhie, Christopher Gordon, Janice R Aldrich-Wright |
Journal | Journal of inorganic biochemistry
(J Inorg Biochem)
Vol. 226
Pg. 111629
(01 2022)
ISSN: 1873-3344 [Electronic] United States |
PMID | 34740037
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Inc. All rights reserved. |
Chemical References |
- Coordination Complexes
- Cytotoxins
- Ruthenium
|
Topics |
- Cell Line
- Coordination Complexes
(chemical synthesis, chemistry, pharmacology)
- Cytotoxins
(chemical synthesis, chemistry, pharmacology)
- Humans
- Ruthenium
(chemistry)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|